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Abstract
Background: With declining vectorial transmission, Chagas disease predominantly affects adults nowadays. The
efficacy of nifurtimox in the chronic phase in adult patients is poorly known, particularly in regions where there is
no risk of reinfection. Recommendations for treatment outcome assessment rely on serological follow-up. We
evaluated the serological and parasitological response to nifurtimox in a cohort of adult patients three years
post-treatment in Switzerland.
Methods: Patients treated with nifurtimox in 2008 during a cross-sectional study in Geneva, Switzerland, were
contacted for follow-up in 2011. Two ELISAs and a rapid immunochromatographic test were used to test 2008 and
2011 serum samples simultaneously. In addition, conventional and real-time PCR were performed on 2011 samples.
Results: Thirty-seven (84.1%) of 44 eligible patients, predominantly female, middle-aged, Bolivians at the
indeterminate stage, were enrolled. All 2011 ELISA and immunochromatographic tests were positive. Twenty-eight
(75.7%) patients presented a lower optical density (OD) in 2011 compared to 2008. This OD difference was
significant in both commercial (P < 0.001) and in-house (P = 0.002) ELISAs. Agreement between the two ELISAs was
low (Kappa = 0.469). All patients had negative conventional PCR results but one (2.7%) was positive with real-time
PCR.
Conclusion: Our results highlight the inadequacy of serology for assessing response in adults, three years after
treatment. In our cohort, 97.3% had results that could either indicate treatment failure or persistant humoral
response despite treatment. The lack of accurate early post-treatment tests of cure prevents appropriate patients
information and councelling. New follow-up tests are needed to assess treatments efficacy given the large adult
population in need of antiparasitic therapy.
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Background
Chagas disease affects 8–10 million people in Latin
America and up to 80,000 and 300,000 in Europe and in
the United States respectively, two areas free from vec-
torial transmission [1,2]. With declining rates of vector-
ial infection, the burden of this chronic disease is now
predominantly carried by adults [3]. Recent guidelines
and practices in non-endemic countries extended treat-
ment indications to adults at the indeterminate phase or
with mild cardiopathy, to prevent or mitigate potentially
lethal cardiac damage [4,5]. Benznidazole and nifurti-
mox are the only antiparasitic drugs registered for this
indication. The significant side-effects and drop-out
rates in adults raises safety and efficiency concerns
about the large scale implementation of adult treatment
programmes [6,7].
The main criterion for treatment success is return to
sereonegativity against T.cruzi [8]. To date, most post treat-
ment serological studies in adults have been conducted in
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patients treated with benznidazole [9]. This drug is fre-
quently recommended by experts as the first line treatment
due to its greater tolerance, even though no randomized
trial has ever evaluated the comparative safety and efficacy
of nifurtimox and benznidazole in adults [7,10]. There has
been no follow-up study of nifurtimox treated patients in
non endemic regions, where the persistance of a seroposi-
tive result cannot be attributed to vectorial reinfection.
Recently, rapid diagnostic tests have proved both sensi-
tive and highly specific in screening adults for Chagas dis-
ease [11,12]. They facilitate the screening of hard-to-reach
populations such as rural communities or migrants in
conditions where access to laboratory is difficult. Conven-
tional serologies should be used to confirm the diagnosis.
No study has evaluated their use as a follow-up tool post-
treatment. Conventional polymerase chain reaction (PCR)
has been found to lack sensitivity in adults at the chronic
phase of the disease when used as a first-line diagnostic
test [13]. This results from the low and intermittent circu-
lating parasitic load in adults during the chronic phase.
No information is available about PCR in adults following
nifurtimox treatment.
This study aimed to observe the changes in conven-
tional and rapid serological diagnostic tests in a cohort of
adults living in a non-endemic country after nifurtimox
treatment. The presence of circulating T. cruzi detected
by conventional and real-time PCR in this cohort was also
examined. We found that all follow-up serological tests
three years after treatment remained positive with one pa-
tient having a positive real-time PCR. It means that 97.3%
of patients could not be classified as either suffering treat-




The protocol of this study was approved by the Ethical
Board for Medical Research of the Geneva University
Hospitals (protocol 11–162). Written informed consent
was obtained from all participants.
Study design and setting
This cohort study took place at the Geneva University
Hospitals, which are the reference center for the screening
and clinical management of Chagas disease in Geneva,
Switzerland. Geneva hosts a substantial population of Latin
American migrants originating from endemic areas for
Chagas disease. Migrants’ communities and support groups
were informed about the study.
Study population
In 2008, we diagnosed Trypanosoma cruzi infection in 130
of 1012 (12.8%) adult Latin American migrants participat-
ing in a community-based cross-sectional study in Geneva,
Switzerland [14]. The diagnosis was based on positive
results in two different serological tests (BioMerieux
Elisa cruziW and the Biokit Bioelisa ChagasW). All partici-
pants with positive results were also tested with a rapid
diagnostic test (Stat-PakW). At that time, no PCR was
performed to search for circulating T. cruzi. The 130 cases
were at the chronic phase of the infection with 14 (11.3%)
and 1 (0.8%) showing evidence of T. cruzi cardiac and
digestive damage, respectively. Eighty-one participants
started treatment with nifurtimox (10 mg/kg/day), how-
ever only 41 of these (56.2%) completed the 60-day treat-
ment. Participants provided informed consent to have
serum samples stored for future Chagas disease diagnostic
studies. Sera were frozen (−20C) upon collection and
stored in a bio-bank at the Geneva University Hospitals.
Study participants
From October 3rd to November 30th 2011, patients diag-
nosed with Chagas disease and who started nifurtimox
treatment during the 2008 study and still living in Geneva
(n = 44) were invited to participate. Patients were con-
tacted by phone by the study nurse. In the event of five
unanswered phone calls, an invitation letter was sent to
the last recorded address. Study information, consent
form and convocation letters were written in Spanish to
enhance participation.
Samples collection
A qualified nurse collected two blood samples from each
participant’s cubital vein: one tube containing EDTA for
PCR and one tube without anticoagulant for serological
tests, the latter being centrifuged and aliquoted in three
subsamples. All samples were stored at −20C within
1 hour upon collection. One frozen serum aliquot per
participant was sent to the National Reference Center for
Parasitology, Research Institute of the McGill University
Health Centre, Montreal General Hospital, Canada for in
house ELISA and PCR testing.
Patient characteristics
Sociodemographic characteristics were collected by the
study nurse at the time of the blood sample collection. In-
formation was cross-checked with those from the 2008
study. Clinical information on the stage of the disease,
2008 serum rapid immunochromatographic assay results
and details about anti-trypanosomal therapy was extracted
from the 2008 study files.
Serological follow-up
In Geneva, the Stat-PakW was performed on one of the
serum aliquots according to the manufacturer’s recom-
mendations. Results were recorded as positive or negative.
After retrieving one 2008 serum aliquot for each partici-
pant, the 2008 and 2011 serum samples were tested with
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the Biokit Bioelisa ChagasW ELISA. All tests were done
simultaneously using the same batch of tests and on the
same machine to reduce random variability in measure-
ments. In Montreal, all 2008 and 2011 samples were
simultaneously tested with an in-house ELISA using fixed
forms of Trypanosoma cruzi (epimastigotes, amastigotes,
and trypomastigotes) as described elsewhere [15]. The
cut-off value of the optical density (OD) for negativity of
the Biokit Bioelisa ChagasW was 0.320, as instructed by
the manufacturer and 0.4 for the in-house ELISA. Results
were reported as a continuous variable for the measure-
ment of OD values and as a categorical variable for the
final result (positive versus negative). No cut-off for clinical
significance was set for the interpretation of the quantita-
tive OD value difference in absence of valid evidences and
following the manufacturer’s recommendation.
PCR assays
DNA extraction was performed from whole blood samples
using QIAamp DNA Mini Kit (Qiagen, San Diego, CA)
following the manufacturer’s instructions. Conventional
PCR was performed as described by Ndao et al. [16].
LightCycler PCR detection and analysis systems (LightCy-
cler 1.5, Roche Applied Science, Manheim, Germany)
were used for amplification and quantification. The reac-
tion was performed in glass capillaries. T. cruzi specific
primers TCZ-3 50--TGC ACT CGG CTG ATC GTT T-30-
and TCZ-4 50--ATT CCT CCA AGC AGC GGA TA-30-
(Ndao et al.) [16] and probe TcruziTM50-6FAM-TGC TGC
ATC ACA CGT TGT GGT CCA—BBQ-30 (TIB MOL-
BIOL, Adelphia, NJ), were designed to amplify the para-
sitic genomic DNA. For amplification detection, the
LightCycler™ Fastart TaqManW Master Kit (Roche Ap-
plied Science) was used as recommended by the manufac-
turer. Briefly, a total of 20 μl of reaction consists of 2 μl
each of primers TCZ-3 and TCZ-4 (1 μM final concentra-
tion), 2 μl (0.4 μM) of Tcruzi TM, 4 μl of 5x reaction
buffer mix and 5 μl distilled H2O. Each sample was ana-
lysed in triplicate, and 5 μl of DNA sample was added in
each capillary. The qPCR reaction was performed with the
cycle condition of 1 cycle at 95C for 10 min, 45 cycles of
95C for 10 s, 61C for 8 s, and 72C for 20s and 1 final
cycle of 40C for 30 s. The cycle number, determined by
the melting curve, was presented as the number of PCR
cycles needed for the fluoresce signal of the amplified pro-
ducts to exceed the detected threshold value.
Statistical analysis
Continuous non-normally distributed variables are pre-
sented with median and interquartile range (IQR). We
used the parametric paired t-test and the non-parametric
Wilcoxon rank sum test to compare 2008 and 2011 OD
values. Fischer’s exact and McNemar’s tests were used for
comparison of independent and paired proportions. The
significance level was set at 0.05%. Analyses were con-
ducted using SPSS software, version 20.
Results
Patients
Of the 44 eligible patients, 37 (84.1%) were enrolled in
the study, while 3 (6.8%) refused to participate and 4
(9.1%) could not be reached. Table 1 shows the sociode-
mographic and clinical characteristics of the 37 partici-
pants. The 7 non participants had similar characteristics
(data not shown).
ELISA and rapid immunochromatographic tests
All 37 post-treatment results were positive with the two
ELISAs and the rapid immunochromatographic test
(Table 2). Twenty-eight (75.7%) participants had decreased
ELISA OD values in 2011 compared to 2008 with signifi-
cantly lower OD values in both the Biokit Bioelisa Chagas
(P < 0.001) and the in-house ELISA (P = 0.002). Agree-
ment between the two tests was low (Kappa = 0.469).
There was no significant association between the propor-
tions of patients with reduced OD value in 2011 and
gender (P = 0.66), age (P = 0.45), stage of disease (P = 1)
and treatment duration (P = 0.69).
PCR testing
Conventional PCR testing was negative in all 37 patients,
whereas real-time PCR was positive in 1 (2.7%) patient.
Discussion
This study shows that none of two ELISAs and a rapid
immunochromatographic test (Stat-PakW) reverted to
negativity three years after nifurtimox treatment in a co-
hort of adults at the chronic stage of Chagas disease living
in an area without vectorial transmission. One patient was
found positive by Real-Time PCR. Therefore, 97.3% parti-
cipants could not be adequately informed about their
current clinical status, with a single patient conclusively
found to be still infected. The positive serological test
results could either indicate treatment failure or simply re-
flect the window period of persistent humoral response
despite potential treatment efficacy. Moreover, we found
low agreement between the two ELISAs in regards to de-
creasing OD values post treatment. Whereas the main
limitation of the study is the sample size of 37 partici-
pants, it is the largest serological follow-up study of adults
treated with nifurtimox published to date and the first
study carried out in a non-endemic country.
To date, there is no early marker of treatment efficacy in
adults. Currently, the criterion of treatment success is the
return to negativity of a previously positive serological test
and it is recommended to undergo a 10- to 20-year long
serological follow-up to assess treatment efficacy in adults
[8]. These recommendations are more appropriate for the
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management of children, whose serology usually return to
negativity within months. Our findings highlight the lack
of utility of these recommendations for adults in clinical
settings as all qualitative serological results remained un-
changed 3 years after treatment with nifurtimox.
These results, in patients with no risk of vectorial
reinfection following treatment, confirm the long lasting
anti-T. cruzi humoral response after treatment, which can
persist for more than 20 years [17-20]. In addition to
showing this long window period, these studies in adults
treated with benznidazole and nifurtimox found overall
low (<50%) seronegativation rates. There is evidence that
a seronegative response following benznidazole treatment
is correlated with a reduced risk of cardiac damage and
possibly of mortality [17,20,21]. Few studies have specifi-
cally evaluated serological response following nifurtimox
treatment in adults. Fabbro and colleagues followed a
cohort of 27 adults over 21 years in Argentina. They found
a trend towards a higher rate of seronegativation in those
treated with nifurtimox (40.5%) than with benznidazole
(33.3%) [17]. Coura et al., found no serological change in
19 Brazilian patients, one year after nifurtimox treatment
[18]. In our cohort, there was no way to reliably discrimin-
ate between treatment failure and latency before seronega-
tivation, except for the single patient with a positive PCR
indicating treatment failure. Moreover, the low agreement
between tests regarding OD kinetic tends to demonstrate
the lack of utility of this potential criterion of cure. We
observed a significant decrease in optical density levels in
both ELISAs tests in 75.7% patients. The exact significance
of this finding is difficult to assess, but a non-randomized
study performed following treatment with benznidazole
showed a positive correlation between declining antibody
titers and a reduction in the risk of cardiac damage [20]. In
Argentina, Fabbro et al. showed that changes in antibody
titers occurred 7 years or later after nifurtimox treatment
[17]. The ongoing BENEFIT cohort study will provide add-
itional information on the serological kinetic and the
protective effect of benznidazole - but not nifurtimox - in
adults [22].
No follow-up study has addressed the evolution of
rapid diagnostic test results after treatment. In our study
population, the Stat-PakW rapid immunochromatogaphic
test has proved reliable at the diagnostic stage [11].
However, after three years, all rapid tests remained posi-
tive, which is consistent with ELISA results. Therefore,
the Stat-PakW cannot be recommended as a test of cure,
at least in the three year post-treatment period.
Different PCR techniques and primers are used to de-
tect circulating T.cruzi. Overall, they are not appropriate
to diagnose the chronic stage of infection due to limited
(60-90%) sensitivity, technical challenges and lack of
standardization [10,13,23]. However, PCR is useful in veri-
fying infection where there are contradictory serological
results, and to confirm treatment failure where there are
persistent seropositive results following treatment. Real-
time PCR is considered more sensitive for parasite detec-
tion than conventional methods and therefore may be a
better tool to assess treatment failure [24]. In this study,
we used two PCR techniques and found a discordant
result in one (2.7%) patient and concordant negative
results in all others. In the absence of pre-treatment PCR
measurements, we were not able to identify changes. PCR
is constantly evolving and efforts are underway to
standardize methods [13]. Further studies are needed to
assess their exact role as a test of cure.
The limited efficacy of currently available treatments and
the lack of rapidly responsive tests of cure have a signifi-
cant impact on the clinical management of adults and on
public health. In our experience, the inability of clinicians
to propose rapid and appropriate information on the treat-
ment outcome soon after its completion may create some
resistance in patients during the pre-treatment information
session. Some of our patients have been reluctant to start a




Gender Male 7 (18.9)
Female 30 (81.1)
Age (years) 44 (25–59)
Origin Bolivia 36 (97.3)
Argentina 1 (2.7)
Staging Indeterminate 31 (83.8)
Cardiopathy 6 (16.2)
Duration of treatment (days) 60 25 (67.6)
30–59 4 (10.8)
<30 8 (21.6)
Table 2 Results of ELISA, rapid immunochromatographic and PCR (conventional and real-time) tests in 37 patients





Conventional PCR Real time PCR
n (%) n (%) n (%) n (%) n (%)
Positive 37 (100) 37 (100) 37 (100) 0 (0) 1 (2.7)
Negative 0 (0) 0 (0) 0 (0) 37 (100) 36 (97.3)
Inconclusive 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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long and potentially poorly tolerated treatment in absence
of a rapidly measurable outcome. Moreover, clinicians are
unable to adequately inform treated patients on their sub-
sequent risk of cardiopathy as long as the tests remain
positive. This hampers personalized counseling on follow-
up and forces patients to undergo serial serological tests
over years. Today’s patients are highly mobile and Chagas
disease has become a global health problem [25]. Inter-
national migrants with Chagas disease, amounting to half
a million at least, may receive treatment in one country
and subsequently move to another, making the currently
recommended long-term serological follow-up highly im-
practicable [25]. Moreover, given the frequent presence of
other modifiable cardiac risk factors in adults with Chagas
disease, the lack of accurate post-treatment evaluation
strategies hamper clinicians in differentiating between
possible causes of subsequent cardiac damage [26]. The
reliance on the return to negativity of serologies as a proof
of treatment success means that treated patients are denied
the opportunity to donate blood and organs for many years
until tests may eventually become negative. This is unfor-
tunate as Latino American migrants are more willing to
donate blood than local residents in Switzerland [14].
Finally, new treatment evaluation is made difficult in ab-
sence of early marker of cure.
Conclusions
In conclusion, currently recommended strategies to assess
treatment outcome in adults, at least in those receiving
nifurtimox, are useless in clinical setting given the ex-
tremely long time-frame necessary to identify change, and
rapid diagnostic tests seem not to offer a valid alternative.
In addition to searching for reactive antigens, new diag-
nostic techniques such as proteomics, flow cytometry and
the monitoring of T. cruzi specific T cells response are
currently under investigation and will hopefully improve
the early assessment of treatment outcome [27-30]. The
management of adult Chagas disease needs rapid progress.
More efficient and safer treatments, together with accur-
ate and early post-treatment tests of cure, will bring about
a giant leap forward in the clinical management of mil-
lions of adult patients.
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